Stifel Resumes Mirum Pharmaceuticals (MIRM) at Buy, PT $89, 'stands out in what remains a discerning biotech tape'

Stifel analyst James Condulis resumes coverage on Mirum Pharmaceuticals (NASDAQ: MIRM) with a Buy rating and a price target of $89.00.

The analyst comments "We're resuming coverage of Mirum with a Buy rating and an $89 target price. Mirum is a unique rare disease biotech with: (1) a cash-flow positive, high-growth commercial business; and (2) a mid-/latestage pipeline with multiple credible growth opportunities, including a near(ish)-term catalyst (PSC pivotal 2Q26). More specifically, we're bullish on Livmarli's growth prospects where, with multiple upside-levers (organic ALGS/PFIC growth, weight-based pricing, EXPAND) alongside a steady/growing stream of Ctexli/ Cholbam revenues, we'd argue these opportunities alone can largely support today's valuation. Against this backdrop, we have strong conviction in volixibat ahead of pivotal PSC/PBC data where--even with conservative assumptions--we comfortably model a blockbuster opportunity. Meanwhile, though earlier and high-risk, FXS offers significant upside-biased optionality. And ultimately, with the above (strong financial position, growing commercial business, pipeline optionality) and a strong management team, we think MIRM stands out in what remains a discerning biotech tape--even as shares have performed well."

For an analyst ratings summary and ratings history on Mirum Pharmaceuticals click here. For more ratings news on Mirum Pharmaceuticals click here.

Shares of Mirum Pharmaceuticals closed at $59.97 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Boeing lands two U.S. defense contracts worth over $711M
• Raymond James Starts SpyGlass Pharma (SGP) at Outperform